Home
Journal Information
About
Aims and Scope
Contact Us
Editorial Board
Editor in Chief
Editorial Policies
Publication Ethics
Indexing/Abstracting
Peer review prosess
Publication Fee
Publisher
Editorial Board Policy
Human and Animal Rights
Journal Issues
Current Issue
In Press
All Issues
Guidelines
For Authors
For Reviewers
Call for Papers
Editorial Workflow
Implications
Informed Consent
Checklist for Review
Disclaimer
Conflicts of Interests
Create Account
Login
Title
Author
Abstract
Keywords
First Name
Last Name
Search
eISSN
:
2345-5004
J Herbmed Pharmacol
. 2019;8(1): 28-34. doi:
10.15171/jhp.2019.05
Original Article
Protective and anti-inflammatory effects of silymarin on paraquat-induced nephrotoxicity in rats
Ali Sharifi-Rigi
1
, Esfandiar Heidarian
2
*
Cited by CrossRef: 5
1- Çomaklı S, Kandemir F, Küçükler S, Özdemir S. Morin mitigates ifosfamide induced nephrotoxicity by regulation of NF-kappaB/p53 and Bcl-2 expression.
Biotechnic & Histochemistry
. 2022;97(6):423
[Crossref]
2- Ujowundu C, Anaba P, Ulinasombu N, Ujowundu F, Igwe K, Ogbuagu H. Attenuation of Paraquat-Induced Nephrotoxicity and Dysfunction in Male Wistar Albino Rats.
Innov Biosyst Bioeng
. 2020;4(1):26
[Crossref]
3- Nouri A, Heibati F, Heidarian E. Gallic acid exerts anti-inflammatory, anti-oxidative stress, and nephroprotective effects against paraquat-induced renal injury in male rats.
Naunyn-Schmiedeberg's Arch Pharmacol
. 2021;394(1):1
[Crossref]
4- Shakerinasab N, Azizi M, Mansourian M, Sadeghi H, Salaminia S, Abbasi R, Shahaboddin M, Doustimotlagh A. Empagliflozin Exhibits Hepatoprotective Effects Against Bile Duct Ligation-induced Liver Injury in Rats: A Combined Molecular Docking Approach to In Vivo Studies.
CPD
. 2022;28(40):3313
[Crossref]
5- Kesharwani S, Jain V, Dey S, Sharma S, Mallya P, Kumar V. An overview of advanced formulation and nanotechnology-based approaches for solubility and bioavailability enhancement of silymarin.
Journal of Drug Delivery Science and Technology
. 2020;60:102021
[Crossref]
Submit Your Paper
Editorial Board
Aims and Scope
Editorial Policies
Ethics
Contact Us
Archive
2.7
2022
CiteScore
29th percentile
Powered by